Search results for "osteonecrosis of the jaws"
showing 10 items of 15 documents
Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018
2018
OBJECTIVES: The task of this working group was to update the knowledge about the use of drugs and biologicals affecting healing of soft tissue and bone during implant treatment or procedures associated with it. Moreover, the impact of titanium particles and biocorrosion on complications and implant survival has been analysed. MATERIALS AND METHODS: The literature in the areas of interest (platelet concentrates, antiresorptive drugs as well as implant-host interaction) was screened using systematic reviews for the former two areas, whereas a narrative critical review was performed for the latter topic. Two manuscripts on platelet concentrates, one manuscript on antiresorptive drugs and one m…
Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retro…
2012
Abstract PURPOSE: The aim of this study was to evaluate the results of the surgical treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in a large cohort. MATERIALS AND METHODS: A retrospective cohort multicenter study was designed. Patients were enrolled if they were diagnosed with BRONJ and received operative treatment. Data on demographic, health status, perioperative, and surgical factors were collected retrospectively. The primary outcome variable was a change in BRONJ staging (improvement, worsening, or no change). Interventions were grouped by local debridement and resective surgery. Data were collected for other variables as cofactors. Univariate analysis and logist…
Bisphosphonate related osteonecrosis of the jaws in Italy: an observational report of 24 cases
2018
Conservative surgical treatment of medication-related osteonecrosis of the jaws with Leukocyte-Platelet Rich Fibrin: preliminary results at nine mont…
2019
IMAGING FINDINGS SYSTEMATIZATION AND IMAGING STAGING PROPOSAL IN BISPHOSPHONATES ASSOCIATED OSTEOMYLITIS/OSTEONECROSIS OF THE JAWS
2011
INTRODUZIONE I Bifosfonati (BPs), farmaci analoghi al pirofosfato, sono usati nel trattamento dell’osteoporosi, nella malattia di Paget, nel mieloma multiplo e nelle metastasi ossee. Sebbene siano molto utili nella sintomatologia osteolitica, dal 2003 è stata descritta la correlazione tra la loro somministrazione e l’insorgenza dell’osteonecrosi dei mascellari (BRONJ). Il nostro studio si propone di descrivere la superiorità delle immagini TC nei pazienti in cura con BPs affetti da BRONJ, e di raggruppare gli stessi in accordo con una classificazione radiologica basata sulla presenza o meno dei segni dell’osteomielite/osteonecrosi e delle successive complicanze. Si dimostra, inoltre, l’impo…
Platelet-Rich Plasma (PRP) in Dental Extraction of Patients at Risk of Bisphosphonate-Related Osteonecrosis of the Jaws: A Two-Year Longitudinal Study
2020
: Dental extraction has often been described as the main trigger event of osteonecrosis of the jaws (ONJ). This longitudinal hospital-based study aimed to evaluate the outcome at 2 years of a standardized medical-surgical protocol for dental extraction, combined with platelet rich-plasma (PRP) application, compared with conventional protocol not combined with PRP or any other autologous platelet concentrate in cancer (ONC) and osteometabolic (OST) patients, at risk of bisphosphonate (BP)-related ONJ. Twenty patients were consecutively recruited: six received BPs for cancer skeletal-related events (34.17 ±
Medication-related osteonecrosis of the jaws. A large multicentric case-and-control retrospective review
2019
Simplifying the dental/periodontal management of patients with metabolic bone fragility receiving treatment with denosumab
2020
Denosumab (DNB) is a bone-targeted medication used to preserve structural integrity and minimise the risk of fragility fractures in metastatic cancer and metabolic bone disorders. DNB targets and binds RANK Ligand, inhibiting osteoclast maturation, function, and survival. In contrast with nitrogen-containing bisphosphonates (N-BPs), DNB does not bind to hydroxyapatite and incorporate into bone; thus, bone cellular remodelling recovers rapidly after drug suspension. Denosumab has benn linked to the occurrence of osteonecrosis of the jaw (MRONJ), a uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Althou…
Proceedings of the Closed Round Table and Italian Consensus on the Medication-Related Osteonecrosis of Jaws (MRONJ) at the Symposium of Italian Socie…
2019
On 20 October 2018 a Closed Round Table brought together a wide range of stakeholders from several medical disciplines, including academic experts, dentists, oncologists, maxillo-facial surgeons, oral surgeons, radiologists, under the technical and scientific coordination of Giuseppina Campisi (for SIPMO) and Giacomo Oteri (for Italian Society of Oral Surgery- SIdCO)
Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?
2013
Osteonecrosis of the jaw (ONJ) is a rare but serious lesion of the jaw, characterized mainly by exposed necrotic bone;it is related to various drugs, usually used for treating patients with advanced malignancies. Drugs implicated in ONJ are: nitrogen-containing bisphosphonates (NBPs), denosumab, anti-angiogenic drugs (e.g bevacizumab, sunitinib,sorafenib) and the selective mammalian target of rapamycin mTOR, everolimus. Previous data regarding the combining of NBPs with antiangiogenic agents conflict with some reports (indicating a similar risk of ONJ compared with the use of NBPs alone1); other reports show significantly higher rates (18% vs 1% with NBPs alone) of the incidence of ONJ2. Th…